Volume 2.37 | Sep 30

Mammary Cell News 2.37 September 30, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Bone-Diease Drug Could Treat Breast Cancer  ShareThis
Two studies published in Nature show how one ingredient of hormone-replacement therapy, a synthetic version of the hormone progesterone called a progestin, can cause breast cancer in mice by activating the protein RANKL. [Press release from Nature News discussing online prepublication in Nature]

ALDEFLUORBreastCSC_645x110



SPECIAL FEATURE

Interested in recruiting talented individuals? Post your career opportunities in Mammary Cell News at no cost. Contact us at [email protected]



SCIENCE NEWS

Yale Researchers Find Protein is a Key Tool in Chromosomal Repair Kit
Scientists have discovered how one protein plays a key role in repairing damage to chromosomes that can cause different types of cancer. [Press release from Yale University discussing online prepublication in Nature Structural & Molecular Biology]

Triple-Negative Breast Cancers May Have Unique Therapeutic Target
Patients with triple-negative breast cancer, one of the hardest subtypes to treat, may have a unique biomarker that would enable them to receive more targeted therapy. [Press release from the American Association for Cancer Research (AACR) discussing data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development]

Circulating Tumor Cells Can Provide ‘Real-time’ Information on Patient’s Current Disease State
Circulating tumor cells may be a promising alternative, noninvasive source of tumor materials for biomarker assessment. [Press release from the American Association for Cancer Research (AACR) discussing data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development]

Novel Biomarker May Predict Response to New VEGF Receptor Inhibitor
Researchers believe there may be a way to predict, based on individual tumors, those patients who are more likely to respond to the investigational new drug tivozanib. [Press release from the American Association for Cancer Research (AACR) discussing data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development]

Increased Risk of Other Cancers for Relatives of Women with Early Onset Breast Cancer
Close relatives of women diagnosed with breast cancer before the age of 35 years are at an increased risk of developing other cancers, according to a study. [Press release from the University of Melbourne discussing online prepublication in the British Journal of Cancer]

Mayo Collaboration Finds Source of Breast Drug Side Effect
Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. [Press release from the University of Melbourne discussing online prepublication in the Journal of Clinical Oncology]

Cancer-Associated Long Non-Coding RNA Regulates Pre-mRNA Splicing
Researchers report that MALAT1, a long non-coding RNA that is implicated in certain cancers, regulates pre-mRNA splicing. [Press release from the University of Illinois discussing online prepublication in Molecular Cell]

MammoCultBreastCancer_645x110_v01


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

RANK Ligand Mediates Progestin-Induced Mammary Epithelial Proliferation and Carcinogenesis
The current study highlights a potential role for RANKL inhibition in the management of proliferative breast disease. [Nature]

Osteoclast Differentiation Factor RANKL Controls Development of Progestin-Driven Mammary Cancer
Here, researchers show that the in vivo administration of medroxyprogesterone acetate triggers massive induction of the key osteoclast differentiation factor RANKL (receptor activator of NF-kappaB ligand) in mammary-gland epithelial cells. [Nature]

Cooperation of Breast Cancer Proteins PALB2 and Piccolo BRCA2 in Stimulating Homologous Recombination
Inherited mutations in human PALB2 are associated with a predisposition to breast and pancreatic cancers. The studies provide the first biochemical insights into PALB2’s function with piccolo BRCA2 as a mediator of homologous recombination in DNA double-strand break repair. [Nat Struct Mol Biol]

Phosphorylation of eEF1A1 at Ser300 by TBetaR-I Results in Inhibition of mRNA Translation
Phosphorylation of eEF1A1 by type I TGF-beta receptor is a novel regulatory mechanism that provides a direct link to regulation of protein synthesis by TGF-beta, as an important component in the TGF-beta-dependent regulation of protein synthesis and cell proliferation. [Curr Biol]

Cooperation of Tissue Factor Cytoplasmic Domain and PAR2 Signaling in Breast Cancer Development
Here, researchers show that cancer cell PAR2 signaling promotes angiogenesis independent of PAR2 phosphorylation at the recognized beta-arrestin recruitment site. [Blood]

LIM Kinases are Required for Invasive Path Generation by Tumor and Tumor-Associated Stromal Cells
Using siRNA-mediated knockdown or a novel small molecule inhibitor, researchers show LIMK was required for path generation by leading tumor cells and nontumor stromal cells during collective tumor cell invasion. [J Cell Biol]

WNT11 Expression is Induced by ERRAlpha and Beta-Catenin and Acts in an Autocrine Manner to Increase Cancer Cell Migration
The data provide evidence for an autocrine regulatory loop involving transcriptional upregulation of WNT11 by ERRalpha and beta-catenin that influences the migratory capacity of cancer cells. [Cancer Res]

CLINICAL RESEARCH

Value of Early Referral to Fertility Preservation in Young Women With Breast Cancer
The purpose of this study was to determine whether early referral to reproductive specialists improves fertility preservation outcomes and reduces delay in adjuvant treatment in young women with breast cancer. [J Clin Oncol]

Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors
Researchers performed a case-control genome-wide association study to identify single nucleotide polymorphisms associated with musculoskeletal adverse events in women treated with aromatase inhibitors for early breast cancer. [J Clin Oncol]



INDUSTRY NEWS

Quantum Immunologics Announces Clinical Study Collaboration with Florida Cancer Institute-New Hope
Quantum Immunologics, Inc., is pleased to announce that it has completed a Clinical Study Agreement with Florida Cancer Institute-New Hope. [Florida Cancer Institute-New Hope Press Release]

Cellceutix Nearing Completion of Toxicity Studies for Its Cancer Compound for the Treatment of Resistant Lung and Breast Cancers
Cellceutix Corporation announced that it has completed its first species toxicity study under the conditions prescribed by United States Food and Drug Administration (FDA) Good Laboratory Practices regulations. [MarketWire]



POLICY NEWS

NIH Grants Will Advance Studies of the Form and Function of Proteins
The National Institutes of Health has awarded 23 grants for structural biology research totaling up to $290 million over five years. [National Institutes of Health, United States]

NCBI Launches the Database of Genomic Structural Variations
The National Institutes of Health announced the launch of a new resource, called the Database of Genomic Structural Variation, or dbVar, to help scientists understand how differences in DNA contribute to human health and disease. [National Institutes of Health, United States]

NIH Releases Biennial Report of the Director
Dr. Francis S. Collins, M.D., Ph.D, director of the National Institutes of Health, announced the release of the Biennial Report of the Director, NIH, for fiscal years 2008 and 2009. The report provides an integrated portrait of NIH research activities, making it easy for Congress, advocates and patient groups and the general public to understand the many activities of the agency. [National Institutes of Health, United States]

The NCI Cancer Immunotherapy Trials Network (CITN) Seeks Member Clinical Sites (NOT-CA-10-034) [National Institutes of Health, United States]

Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR [U43/U44]) (PAR-10-286) [National Institutes of Health, United States]

Office of Biotechnology Activities, Office of Science Policy, Office of the Director; Notice of Meeting (FR Doc. 2010-23947) [National Institutes of Health, United States]

National Center for Research Resources; Notice of Closed Meeting (FR Doc. 2010-23852) [National Institutes of Health, United States]

Center for Scientific Review; Amended Notice of Meeting (FR Doc. 2010-23847) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meeting (FR Doc. 2010-23849) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-23860) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-23952) [National Institutes of Health, United States]



EVENTS (Listed by Date)

Expert Perspectives: Integrating New Data into Best Practices for Breast Cancer
October 1, 2010
National Harbor, United States

2010 Breast Cancer Symposium
October 1-3, 2010
Washington, DC, United States

2010 World Stem Cell Summit
October 4-6, 2010
Detroit, United States

2nd International Inflammatory Breast Cancer Conference
October 6-7, 2010
Marseille, France

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

Institute for Genomic Medicine Inaugural Symposium
October 11-12, 2010
San Diego, United States

New York Stem Cell Foundation 5th Annual Translational Stem Cell Research Conference
October 12-13, 2010
New York City, United States

International Symposium on Breast Cancer Prevention: Nutrition, Communications and Public Policy
October 18-19, 2010
West Lafayette, United States

6th Modern Drug Discovery & Development Summit (M3D)
October 20-22, 2010
San Francisco, United States

16th World Congress of the Senologic International Society
October 20-22, 2010
Valencia, Spain

American Institute for Cancer Research (AICR) 2010 Annual Cancer Research Conference
October 21-22, 2010
Washington, DC, United States

MENA Oncology Conference
October 22-23, 2010
Cairo, Egypt

Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain

2nd Annual Stem Cells Asia and Regenerative Medicine Congress
October 26-28, 2010
Seoul, Korea

UAE Cancer Congress 2010
October 28-30, 2010
Dubai, United Arab Emirates

6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom

9th Annual American Association for Cancer Research (AACR) International Conference: Frontiers in Cancer Prevention Research
November 7-10, 2010
Philadelphia, United States

The 16th International Conference of the International Society of Differentiation: From Stem Cells to Organisms
November 15-18, 2010
Nara, Japan

22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium: Molecular Targets and Cancer Therapeutics
November 16-19, 2010
Berlin, Germany

33rd Annual San Antonio Breast Cancer Symposium
December 8-12, 2010
San Antonio, United States

Epithelial Plasticity and Epithelial to Mesenchymal Transition
January 21-26, 2011
Vancouver, Canada

Select Biosciences 5th Annual Stem Cells World Congress
January 24-25, 2011
San Diego, United States

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

28th Annual Miami Breast Cancer Conference
March 9-12, 2011
Miami, United States

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES

Cell Therapy Technologist (Opexa Therapeutics)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.
Visit here to post your career opportunities.


Have we missed an important article or publication in Mammary Cell News? Click here to submit!


Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us